Glipizide and Oxervate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glipizide (glipizide) and Oxervate (cenegermin-bkbj). Common drug interactions include eye pain among females and eye pain among males.

The phase IV clinical study analyzes what interactions people have when they take Glipizide and Oxervate. It is created by eHealthMe based on reports of 88 people who take the same drugs from the FDA, and is updated regularly.

What is Glipizide?

Glipizide has active ingredients of glipizide. It is often used in diabetes. eHealthMe is studying from 64,852 Glipizide users. Check the latest studies of Glipizide.

What is Oxervate?

Oxervate has active ingredients of cenegermin-bkbj. eHealthMe is studying from 7,219 Oxervate users. Check the latest studies of Oxervate.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 25, 2026

88 people who take Glipizide and Oxervate together, and have interactions are studied.

Glipizide and Oxervate drug interactions.

What are the common drug interactions of Glipizide and Oxervate, by gender? *:

female:

  1. Eye pain
  2. Eye irritation
  3. Ocular hyperaemia (an abnormally large amount of blood in eye)
  4. Vision blurred
  5. Photophobia (extreme sensitivity to light)
  6. Eye infection
  7. Eye swelling
  8. Corneal erosion (failure of the cornea's outermost layer of epithelial cells to attach to the underlying)
  9. Ocular discomfort (a generic expression when there is lack of ease in/about the eyes)
  10. Drug ineffective

male:

  1. Eye pain
  2. Eye irritation
  3. Eyelid pain
  4. Headache (pain in head)
  5. Pneumonia
  6. Eye discharge
  7. Anxiety
  8. Dizziness
  9. Eye infection bacterial
  10. Photophobia (extreme sensitivity to light)

What are the common drug interactions of Glipizide and Oxervate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Back disorder
  2. Nausea (feeling of having an urge to vomit)
  3. Hordeolum (small collection of pus (abscess) on the eyelid)
  4. Ocular hyperaemia (an abnormally large amount of blood in eye)
  5. Asthenopia (eyestrain-tiredness of the eyes caused by prolonged close work by a person with an uncorrected vision problem)
  6. Blepharospasm (any abnormal contraction or twitch of the eyelid)
  7. Dry eye (lack of adequate tears)
  8. Eye irritation
  9. Eye pain
  10. Photophobia (extreme sensitivity to light)

60+:

  1. Eye pain
  2. Ocular hyperaemia (an abnormally large amount of blood in eye)
  3. Dry eye (lack of adequate tears)
  4. Erythema of eyelid (redness of the eyelid)
  5. Foreign body sensation in eyes (feeling of something in eye)
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  8. Drug ineffective
  9. Eye infection
  10. Eye irritation

What are the existing conditions these people have? *

  1. Neurotrophic Keratopathy (decreased corneal sensitivity and poor corneal healing): 79 people, 89.77%
  2. Ulcerative Keratitis (ulcerative inflammation of the cornea): 18 people, 20.45%
  3. Hypoaesthesia Eye (reduced sense of touch or sensation on eyes): 10 people, 11.36%
  4. Dry Eyes (lack of adequate tears): 5 people, 5.68%

* Approximation only. Some reports may have incomplete information.

Do you take Glipizide and Oxervate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Glipizide and Oxervate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glipizide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Oxervate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glipizide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Oxervate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on glipizide and cenegermin-bkbj (the active ingredients of Glipizide and Oxervate, respectively), and Glipizide and Oxervate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: